HCV NATAP (@JulesLevin1) profile picture
Joined December 2013
Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)Photo by HCV NATAP (@JulesLevin1)
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium - Merck.com merck.com/news/merck-and-mod…
66
webinar: Aging & Women with HIV link to register: event.webcasts.com/starthere…
27
HCV NATAP retweeted
Ovarian aging and the "leaky gut" "These findings provide the strongest evidence to date that menopause may promote gut barrier dysfunction and microbial translocation in otherwise-healthy women." @jclinicalinvest jci.org/articles/view/209807
8
144
10
558
40,443
HCV NATAP retweeted
Silent atherosclerosis can start early in life and follows patterns by age and sex throughout the lifespan, from a large cohort of >16,000 participants age 18-70 years #ESCCongress @NEJM nejm.org/doi/full/10.1056/NE…
12
95
10
393
42,379
HCV NATAP retweeted
A probiotic to extend healthspan? A specific gut bacteria was found to be consistently depleted in people with aging. Then "oral B. pseudocatenulatum monotherapy rescued intestinal homeostasis, mitigated multiorgan inflammaging, enhanced cognitive–motor performance and extended healthspan" ......in mice nature.com/articles/s43587-0…
14
164
11
697
53,118
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma merck.com/news/merck-and-mod…
44
HIV Research Round-Up: Results from the International AIDS Conference - 1771744 webinar August 28 Register at this link event.webcasts.com/starthere…
82
Zero HIV acquisitions with twice-yearly subcutaneous lenacapavir for PrEP during 52 weeks of open-label extension in PURPOSE 1 at IAS 2026 Brazil natap.org/2026/IAS/IAS_50.ht…
40
High efficacy of twice-yearly subcutaneous lenacapavir for PrEP through 52 weeks of open-label extension in PURPOSE 2 at IAS 2026 natap.org/2026/IAS/IAS_51.ht…
1
47
HCV NATAP retweeted
How to delay ovary aging? —Exercise —And the potential of targeting adiponectin From 2 large cohorts ~165K participants and extensive studies in mice @NatureAging nature.com/articles/s43587-0…
11
78
5
403
71,861